NeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726

Stock of NeuroBo Pharmaceuticals, Inc. (NRBO) gained 48 percent on Thursday after the FDA approved the company's Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist.

Related Keywords

Canada ,Germany ,German , ,Deutsche Bank ,Merck Co Inc ,Fda ,Nd Application ,Xyntomodulin ,Neurobo Pharmaceuticals ,A 1726 ,Glucagon Receptor ,